Plasminogen activator inhibitor-1 (PAI-1) Gene 4G/5G promoter polymorphism is seen in higher frequency in the Indian patients with deep vein thrombosis

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 2, 2010, Pages 184-188

  Akhter, Mohammed Suhail ^a   Biswas, Arijit ^a   Ranjan, Ravi ^a   Meena, Arvind ^a   Yadav, Birendra Kumar ^a   Sharma, Amit ^a   Saxena, Renu ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

4G 5G polymorphism; Deep vein thrombosis (DVT); Factor V Leiden (FVL); PAI 1

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMORBIDITY; ETHNIC GROUPS; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INDIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK; THROMBOPHILIA; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 77949910652     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609333673     Document Type: Article

References (22)

1. Biswas A., Bajaj J., Ranjan R., et al. Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian Indian patients with deep vein thrombosis ? Clin Chim Acta. 2008 ; 392: 21-24.
2. Alessi M., Juhan-Vague I., Kooistra T., Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor-1 by the human hepatocellular cell line HepG2. Thromb Haemost. 1988 ; 60: 491-494.
3. Sartori MT, Wiman B., Vettore S., Dazzi F., Girolami A., Patrassi GM 4G/5G polymorphism of PAI-1 gene promoter & fibrinolysis capacity in patients with deep vein thrombosis. Thromb Hemost. 1998 ; 80: 956-960.
4. Juhan-Vague I., Vaghe P., Alessi M., et al. Relationship between plasma insuli, triglycerides, body mass index and plasminogen activator inhibitor-1. Diabetes Metab. 1987 ; 13: 331-336.
5. Blasiak J., Smolarz B. Plasminogen activator inhibitor-1I (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochimica Polonica. 2000 ; 47: 191-199.
6. Falk G., Almqvist A., Nordehen A., Svensson H., Wiman B. Allele specific PCR for a detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis. 1995 ; 9: 170-174.
7. Rocha E., Paramo JA The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1. Fibrinolysis. 1994 ; 8: 294-303.
8. Juhan Vague I., Valadier J., Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost. 1987 ; 57: 67-72.
9. Jansson JH, Nilsson TK, Olofsson BO Tissue plasminogen activator inhibitor and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991 ; 2: 157-161.
10. Johansson L., Jansson HJ, Boman K., Nilsson KT, Stegmayr B., Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1 and tissue plasminogen activator/ plasminogen activator inhibitor-1 complex as a risk factors for the development of a first stroke. Stroke. 2000 ; 1: 26-32.
11. Sartori MT, Danesin C., Saggiorato G., et al. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost. 2003 ; 9: 299-307.
12. Eriksson P., Kallin B., Vant Hoft FM, Bavenholm P., Hamsten A. Allele specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995 ; 92: 1851-1855.
13. Mansfield MW, Stickland MH, Grant PJ Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasians patients, with non insulin dependent diabetes mellitus. Thromb Haemost. 1995 ; 74: 842-847.
14. Wiklund GP, Nilsson L., Ardnor NS, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke. Replicated findings in two nested case-control studies based on independent cohorts. Stroke. 2005 ; 36: 1661-1665.
15. Grubic N., Stegnar M., Peternel P., Keider A., Binder BR A novel G/A and the 4G/5G polymorphism with in the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res. 1996 ; 84: 431-443.
16. Ridker PM, Hennekens CH, Lindpaintner K., Stampfer MJ, Miletich JP Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor in a large cohort of US men. Circulation. 1997 ; 95: 59-62.
17. Vague P., Juhan-Vague I., Aillaud MF, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese objects. Metabolism. 1986 ; 35: 250-253.
18. Segui R., Estelles A., Mira Y., et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subject with genetic thrombolic defects. Br J Haematol. 2000 ; 111: 122-128.
19. Naran NH, Chetty N., Crowther NJ The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity. Atherosclerosis. 2008 ; 196: 155-163.
20. Pegoraro RJ, Ranjith N. Plasminogen activator inhibitor type-1 (PAI-1) and platelet glycoprotein IIIa (PG IIIa) polymorphism in young Asian Indians with acute myocardial infarction. Cardiovasc J S Afr. 2005 ; 16: 266-270.
21. Kostka H., Kuhlisch E., Schellong S., Siegert G. Polymorphisms in the TAFI gene and the risk of venous thrombosis. Clin Lab. 2003 ; 49: 645-647.
22. Martini CH, Brandts A., de Bruijne EL, et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol. 2006 ; 134: 92-94.